View : 401 Download: 0
Effects of CYP2D6 genotypes on Plasmodium vivax recurrence after primaquine treatment: A meta-analysis
- Title
- Effects of CYP2D6 genotypes on Plasmodium vivax recurrence after primaquine treatment: A meta-analysis
- Authors
- Park Y.-A.; Park K.H.; Yoon H.Y.; Yee J.; Gwak H.S.
- Ewha Authors
- 곽혜선; 이정
- SCOPUS Author ID
- 이정
- Issue Date
- 2022
- Journal Title
- Travel Medicine and Infectious Disease
- ISSN
- 1477-8939
- Citation
- Travel Medicine and Infectious Disease vol. 48
- Keywords
- CYP2D6 phenotype; Malaria; Pharmacogenomics; Plasmodium vivax; Primaquine; Recurrence
- Publisher
- Elsevier Inc.
- Indexed
- SCIE; SCOPUS
- Document Type
- Article
- Abstract
- Objectives: To elucidate the relationship between CYP2D6 polymorphisms and Plasmodium vivax recurrence in patients receiving primaquine-based treatment through systematic review and meta-analysis. Methods: We searched the PubMed, EMBASE, Cochrane Library, and Web of Science databases for eligible studies published up to August of 2021. We included studies investigating the associations between CYP2D6 polymorphisms and P. vivax recurrence. We evaluated the pooled odds ratio (OR) and 95% confidence interval (CI). Results: Data from nine studies, including 970 patients, were analyzed. We found that CYP2D6 poor metabolizers (PMs), intermediate metabolizers (IMs), or normal metabolizers slow (NM-Ss) were associated with a 1.8-fold (95% CI, 1.34–2.45; P = 0.0001) higher recurrence of P. vivax than normal metabolizers fast (NM-Fs), extensive metabolizers (EMs), or ultrarapid metabolizer (UMs). Subgroup analysis showed that studies on both Brazilian and Southeast or East Asian individuals had similar results to the main results. Sensitivity analysis by sequentially excluding individual studies also showed robust results (OR range: 1.63–2.01). Conclusions: This meta-analysis confirmed that CYP2D6 PMs, IMs, or NM-Ss increased the risk of P. vivax recurrence compared to NM-Fs, EMs, or UMs. The results of this study could be used to predict P. vivax recurrence and suggest CYP2D6 genotype-based primaquine dosing. © 2022
- DOI
- 10.1016/j.tmaid.2022.102333
- Appears in Collections:
- 약학대학 > 약학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML